Search for Clinical Trial Results

Sponsored By

Angioimmunoblastic Lymphadenopathy With Dysproteinemia - 29 Studies Found

Status Study
Completed Study Name: A Phase II Study of Rituximab Combined With CHOP in T-cell Angio-immunoblastic Lymphoma
Condition: Untreated T-cell Angioimmunoblastic Lymphoma
Date: 2005-09-12
Interventions:
  • Drug: Rituximab 375 mg/m2 D1
Completed Study Name: Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma
Condition: Lymphoma
Date: 2009-08-12
Interventions:
  • Drug: cyclophosphamide
  • Drug: fludarabine p
Terminated Study Name: Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma
Condition: Lymphoma
Date: 2003-10-03
Interventions: Drug: cyclosporine Cyclosporine doses will be based on actual body weight unless actual body weight is &
Recruiting Study Name: Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
Condition:
  • Follicular Variant Peripheral T-Cell Lymphoma
  • Recurrent Angioimmunobla
    Date: 2015-08-10
    Interventions:
    • Biological: Anti-ICOS Monoclonal Antibody MEDI-570

Completed Study Name: Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation
Condition:
  • Solid Tumor
  • Glioma
  • Angioimmunoblasti
    Date: 2014-10-16
    Interventions: Drug: AG-221 AG-221 administered orally on every day of 28 day cycles until disease progression or unacc
Recruiting Study Name: A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma
Condition: Lymphoma
Date: 2017-01-16
Interventions: Drug: plitidepsin Other Name: APLD Aplidine
Recruiting Study Name: Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)
Condition: T-cell Lymphoma
Date: 2012-01-20
Interventions: Drug: Lenalidomide Lenalidomide
Recruiting Study Name: Risk Stratification of Nodal PTCL
Condition:
  • Peripheral T-Cell Lymphoma, Not Otherwise Specified
  • Angioimmunoblastic
    Date: 2017-01-31
Recruiting Study Name: Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP
Condition:
  • Peripheral T Cell Lymphoma, Unspecified
  • Angioimmunoblastic Lymphadenop
    Date: 2008-07-25
    Interventions:
    • Biological: alemtuzumab Additi
Recruiting Study Name: CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study
Condition:
  • Peripheral T-cell Lymphoma NOS
  • Anaplastic Large Cell Lymphoma, ALK-Negative
  • Drug: Cyclophosphamide 750mg/m
Next >>>